What a 15-Person Phase 1 Trial Found About CTX310 After One Year

CTX310 is an experimental CRISPR-Cas9 therapy given as a single intravenous infusion. It is designed to disrupt the ANGPTL3 gene in liver cells, reducing production of a protein involved in regulating blood lipids. In a 15-person Phase 1 study, reductions in LDL cholesterol, triglycerides and circulating ANGPTL3 were still reported 12 months after treatment at the highest dose. The findings are promising early evidence, not proof of lasting safety or reduced cardiovascular risk. 246

What changed after 12 months?

Among participants who received the highest dose, mean LDL cholesterol was 52.5% below baseline and mean triglycerides were 47.8% lower at 12 months. The reported mean reduction in circulating ANGPTL3 at that dose was about 79%. These figures describe the highest-dose results, not the average change across all 15 participants. 67

The follow-up suggests that the lipid changes persisted for a year after one infusion. It does not establish how long they will last beyond that period. 69

How CTX310 is intended to work

CTX310 uses CRISPR-Cas9 to make a loss-of-function edit to ANGPTL3 in the liver. The goal is to reduce ANGPTL3 activity and, in turn, lower LDL cholesterol and triglycerides. Unlike a medicine taken repeatedly, CTX310 is being developed as a one-time infusion intended to produce an enduring genetic change. Whether that approach delivers lasting benefits or risks over the long term remains unknown. 24

Why a one-time approach could matter—and what is not yet known

For people whose lipid levels remain uncontrolled despite available treatment, a single treatment that lowers both LDL cholesterol and triglycerides could eventually offer a different way to manage dyslipidemia. But Phase 1 results do not show that CTX310 can replace existing medicines, and the trial did not test whether treatment prevents heart attacks, strokes or other cardiovascular events. 24

Safety findings and limitations

Investigators reported no dose-limiting toxicities or serious adverse events considered related to CTX310 during the reported follow-up. Reported events included infusion-related reactions and a transient rise in liver enzymes. A participant who died months after receiving the lowest dose was judged by investigators to have had an event unrelated to treatment. These assessments are reassuring as initial observations, but a study of 15 people cannot rule out uncommon or delayed harms. 14

The trial’s primary purpose was to assess safety, not to establish clinical benefit. Its small size and early phase also limit what can be concluded about how well the treatment works across different patients or how durable and safe the edit will be over many years. 24

What comes next?

CTX310 is being evaluated in Phase 1b development, with work prioritizing severe hypertriglyceridemia and refractory hypercholesterolemia. Larger studies and longer follow-up will be needed to better assess lipid effects, uncommon or delayed safety issues and whether changing these biomarkers leads to improved health outcomes.